15 completed, 6 active not recruiting, 5 recruiting, 5 unknown. 16 Phase 2, 9 Phase 3, 2 Phase 1, 1 Not applicable, 1 Phase 4.
Follow Hepatitis D, Chronic: new trials by email Literature Review of Hepatitis D, Chronic trials Research Report on Hepatitis D, Chronic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D Hepalatide 2.1mg, Placebo of Hepalatide - Hepatitis D, Chronic | Phase 3 | Not yet recruiting | Shanghai HEP Pharmaceutical Co., Ltd. | 150 | 2027-06-01 | 2026-10-28 |
| Safety and Antiviral Activity of a Monoclonal Hepatitis B Antibody: a Phase 1b, Open-label Trial in Individuals With Chronic Hepatitis D Infection HepB mAb19 - Hepatitis D, Chronic, Hepatitis B Chronic Infection | Phase 1 | Recruiting | Aarhus University Hospital | 15 | 2026-04-23 | 2026-05-28 |
| Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide Brelovitug (BJT-778), Bulevirtide - Chronic Hepatitis D | Phase 2 / Phase 3 | Recruiting | Mirum Pharmaceuticals, Inc. | 120 | 2026-02-26 | 2026-10-27 |
| A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection Tobevibart, Elebsiran, Bulevirtide - Viral Hepatitis | Phase 2 | Active not recruiting | Vir Biotechnology, Inc. | 100 | 2025-08-05 | 2026-01-16 |
| Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus GS-4321, GS-4321 Placebo - Chronic Hepatitis Delta | Phase 1 / Phase 2 | Recruiting | Gilead Sciences | 200 | 2025-07-31 | 2026-08-27 |
| A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide Tobevibart, Elebsiran, Bulevirtide - Viral Hepatitis | Phase 3 | Active not recruiting | Vir Biotechnology, Inc. | 150 | 2025-07-30 | 2026-07-13 |
| A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection Tobevibart, Elebsiran - Viral Hepatitis | Phase 3 | Active not recruiting | Vir Biotechnology, Inc. | 124 | 2025-03-12 | 2026-11-03 |
| Finite Treatment of Hepatitis Delta With Bulevirtide: Identification of Biomarkers Associated With Sustained Control of HDV Infection Stop Treatment with Bulevertide in patients with compensated liver disease and chronic HDV infection - Compensated Liver Disease (Disorder), Hepatitis D, Chronic | Not applicable | Active not recruiting | Hannover Medical School | 20 | 2024-09-30 | 2026-03-03 |
| Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of RBD1016 in Participants With Chronic Hepatitis D RBD1016, Placebo - Chronic Hepatitis D | Phase 2 | Active not recruiting | Ribocure Pharmaceuticals AB | 14 | 2024-08-21 | 2026-10-15 |
| Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis Peginterferon Lambda - Chronic Hepatitis Delta | Phase 2 | Withdrawn | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2024-05-22 | 2024-05-23 | |
| Find HDV and Determine Its Status in Turkey Anti Delta - Chronic Hepatitis D Infection, Fibrosis, Liver | Unknown | Yaşar Bayındır, MD | 20000 | 2024-03-11 | 2024-08-12 | |
| Study of Hepalatide in Chronic Hepatitis D(CHD) Patients Hepalatide, Hepalatide Placebo - Chronic Hepatitis D Infection | Phase 2 | Completed | Shanghai HEP Pharmaceutical Co., Ltd. | 23 | 2023-10-07 | 2024-04-24 |
| Study to Evaluate Efficacy, Safety and Biomarkers of Bulevirtide Treatment in Chronic Hepatitis D Patients Bulevirtide - Chronic Hepatitis D | Recruiting | Karolinska University Hospital | 400 | 2023-09-27 | 2023-09-29 | |
| Incidence of Viral Hepatitis D Relapses Upon Discontinuation of Bulevirtide in Patients With Chronic Hepatitis D and Negative HDV RNA Chronic Hepatitis D | Completed | Center of target therapy | 24 | 2023-09-01 | 2025-04-25 | |
| SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection. VIR-2218, VIR-3434, NRTI - Hepatitis D, Chronic | Phase 2 | Active not recruiting | Vir Biotechnology, Inc. | 95 | 2022-09-17 | 2026-06-26 |
| Burden of Hepatitis D Virus (HDV) Infection in Italy Chronic Hepatitis D | Completed | University of Turin, Italy | 515 | 2022-08-24 | 2025-02-05 | |
| Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection Lonafarnib, Ritonavir - Hepatitis D, Chronic | Phase 3 | Completed | Soroka University Medical Center | 10 | 2021-05-15 | 2026-04-30 |
| A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus JNJ-73763989, Placebo, Entecavir (ETV) monohydrate - Hepatitis D, Chronic | Phase 2 | Completed | Janssen Research & Development, LLC | 52 | 2020-09-17 | 2026-07-22 |
| National Cohort of Patients Co-infected With Hepatitis B and Delta Viruses Blood draw for the laboratory assessment - Hepatitis D, Chronic, Hepatitis B, Chronic | Recruiting | ANRS, Emerging Infectious Diseases | 800 | 2020-02-19 | 2025-02-05 | |
| Study the Content of the HBV DNA in Liver Biopsy in the Patients Chronic Hepatitis Delta liver biopsy - Chronic Hepatitis Delta, Liver Biopsy | Unknown | Tokhirbek Dolimov | 30 | 2019-10-10 | 2019-11-21 |
Showing 20 of 36. Sign in to see all of them.
Hepatitis D (11) · Hepatitis B, Chronic (5) · Hepatitis (4) · Hepatitis B (3) · Digestive System Diseases (2) · Liver Diseases (2) · Carcinoma, Hepatocellular (1) · Fibrosis (1) · Glomerulonephritis (1) · Hepatitis, Chronic (1) · Liver Cirrhosis (1) · Polyarteritis Nodosa (1)
Chronic Disease (36) · Disease Attributes (36) · Hepatitis, Viral, Human (36) · Infections (36) · Pathologic Processes (36) · Pathological Conditions, Signs and Symptoms (36) · RNA Virus Infections (36) · Virus Diseases (36) · Hepatitis, Chronic (35) · Digestive System Diseases (34) · Liver Diseases (34) · Hepatitis (32) · Hepatitis D (25) · Blood-Borne Infections (7) · Communicable Diseases (7)
bulevirtide (6) · peginterferon alfa-2a (4) · Ritonavir (3) · lonafarnib (3) · Ezetimibe (2) · Ribavirin (2) · Tenofovir (2) · myrcludex-B (2) · peginterferon lambda-1a (2) · Blood Specimen Collection (1) · Lamivudine (1) · entecavir (1) · peginterferon alfa-2b (1) · tenofovir alafenamide (1)
Hoffmann-La Roche (4) · Vir Biotechnology, Inc. (4) · Gilead Sciences (3) · EIT Pharma, Inc. (2) · Mirum Pharmaceuticals, Inc. (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · Shanghai HEP Pharmaceutical Co., Ltd. (2) · ANRS, Emerging Infectious Diseases (1) · Aarhus University Hospital (1) · Aga Khan University (1) · Center of target therapy (1) · Eiger BioPharmaceuticals (1) · Hannover Medical School (1) · Janssen Research & Development, LLC (1) · Karolinska University Hospital (1)
Germany (10) · Italy (9) · Romania (9) · France (7) · United States (7) · Moldova (6) · United Kingdom (6) · New Zealand (5) · Turkey (Türkiye) (5) · Pakistan (4) · Russia (4) · Spain (4) · Sweden (4) · Bulgaria (3) · China (3)
Christopher Koh, M.D. (1) · David Apelian, MD, PhD, MBA (1) · Eduardo B Martins, MD, DPhil (1) · Heiner Wedemeyer, MD, PhD (1) · Junqi Niu (1) · Junqi Niu, Professor (1) · Mario Rizzetto, MD (1) · Nariman Gulyamov, DSci (1) · Ohad Etzion, MD (1)
PMID 41586499, PMID 39648559, PMID 28964701, PMID 30833068, PMID 33553968, PMID 37120031, PMID 38340811, PMID 38842520, PMID 39009085, PMID 41211943, PMID 41405233, PMID 41966308
2019 (2), 2025 (2), 2023 (1)